These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18584174)

  • 41. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways.
    Rush C; Mitchell T; Garside P
    J Immunol; 2002 Nov; 169(9):4951-60. PubMed ID: 12391208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
    Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
    Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.
    Zhang X; Issagholian A; Berg EA; Fishman JB; Nesburn AB; BenMohamed L
    J Virol; 2005 Dec; 79(24):15289-301. PubMed ID: 16306600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
    Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
    Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses.
    Flechtner JB; Cohane KP; Mehta S; Slusarewicz P; Leonard AK; Barber BH; Levey DL; Andjelic S
    J Immunol; 2006 Jul; 177(2):1017-27. PubMed ID: 16818758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.
    Cho HI; Celis E
    Cancer Immunol Immunother; 2012 Mar; 61(3):343-51. PubMed ID: 21915800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.
    Kim D; Monie A; He L; Tsai YC; Hung CF; Wu TC
    Gene Ther; 2008 May; 15(9):677-87. PubMed ID: 18273057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
    Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
    J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.
    Ding C; Wang L; Marroquin J; Yan J
    Blood; 2008 Oct; 112(7):2817-25. PubMed ID: 18669871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4
    Chiodetti AL; Sánchez Vallecillo MF; Dolina JS; Crespo MI; Marin C; Schoenberger SP; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Morón G; Maletto BA
    Front Immunol; 2018; 9():2319. PubMed ID: 30364187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification.
    Pinto PBA; Assis ML; Vallochi AL; Pacheco AR; Lima LM; Quaresma KRL; Pereira BAS; Costa SM; Alves AMB
    Front Immunol; 2019; 10():1522. PubMed ID: 31333657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.
    Cecil DL; Holt GE; Park KH; Gad E; Rastetter L; Childs J; Higgins D; Disis ML
    Cancer Res; 2014 May; 74(10):2710-8. PubMed ID: 24778415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment.
    Yamamoto S; Matsuo K; Nagakubo D; Higashiyama S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
    J Pharmacol Sci; 2018 Mar; 136(3):165-171. PubMed ID: 29519579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.